Year Authors/Creators Item Type Full Text

2023

A global research priority agenda to advance public health responses to fatty liver disease. (2023) Lazarus, Jeffrey V; Mark, Henry E; Allen, Alina M; Arab, Juan Pablo; Carrieri, Patrizia; Noureddin, Mazen; Alazawi, William; Alkhouri, Naim; Alqahtani, Saleh A; Arrese, Marco; Bataller, Ramon; Berg, Thomas; Brennan, Paul N; Burra, Patrizia; Castro-Narro, Graciela E; Cortez-Pinto, Helena; Cusi, Kenneth; Dedes, Nikos; Duseja, Ajay; Francque, Sven M; Hagström, Hannes; Huang, Terry T-K; Wajcman, Dana Ivancovsky; Kautz, Achim; Kopka, Christopher J; Krag, Aleksander; Miller, Veronica; Newsome, Philip N; Rinella, Mary E; Romero, Diana; Sarin, Shiv Kumar; Silva, Marcelo; Spearman, C Wendy; Tsochatzis, Emmanuel A; Valenti, Luca; Villota-Rivas, Marcela; Zelber-Sagi, Shira; Schattenberg, Jörn M; Wong, Vincent Wai-Sun; Younossi, Zobair M; Healthy Livers, Healthy Lives Collaborators

2021

Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens. (2021) Shah, Rajiv; Ahovegbe, Lucrece; Niebel, Marc; Shepherd, James; Thomson, Emma C

2018

A measure of alcohol consumption in late adolescence associated with liver disease after 39 years of follow-up is insufficient to guide alcohol safe limits. (2018) Askgaard, G; Tolstrup, JS; Leon, DA

Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. (2018) Shimakawa, Yusuke; Njie, Ramou; Ndow, Gibril; Vray, Muriel; Mbaye, Papa Saliou; Bonnard, Philippe; Sombié, Roger; Nana, Jean; Leroy, Vincent; Bottero, Julie; Ingiliz, Patrick; Post, Gerrit; Sanneh, Bakary; Baldeh, Ignatius; Suso, Penda; Ceesay, Amie; Jeng, Adam; Njai, Harr Freeya; Nayagam, Shevanthi; D'Alessandro, Umberto; Chemin, Isabelle; Mendy, Maimuna; Thursz, Mark; Lemoine, Maud

2017

High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease. (2017) Hedegaard, Ditte L; Tully, Damien C; Rowe, Ian A; Reynolds, Gary M; Bean, David J; Hu, Ke; Davis, Christopher; Wilhelm, Annika; Ogilvie, Colin B; Power, Karen A; Tarr, Alexander W; Kelly, Deirdre; Allen, Todd M; Balfe, Peter; McKeating, Jane A

2016

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. (2016) Martin, Natasha K; Vickerman, Peter; Dore, Gregory J; Grebely, Jason; Miners, Alec; Cairns, John; Foster, Graham R; Hutchinson, Sharon J; Goldberg, David J; Martin, Thomas CS; Ramsay, Mary; STOP-HCV Consortium; Hickman, Matthew

2013

COST-EFFECTIVENESS OF INCREASING HCV CASE-FINDING FOR PEOPLE WHO INJECT DRUGS VIA DRIED BLOOD SPOT TESTING IN ADDICTION SERVICES AND PRISONS. (2013) Martin, NK; Hickman, M; Miners, A; Hutchinson, SJ; Taylor, A; Vickerman, P

ARE CURRENT TREATMENT RATES SUFFICIENT TO REDUCE HCV PREVALENCE AMONG PEOPLE WHO INJECT DRUGS? MODEL PROJECTIONS IN SEVEN UK SETTINGS. (2013) Martin, NK; Vickerman, P; Clements, A; Cramp, M; de Angeles, D; Dillon, JF; Fahey, S; Foster, GR; Goldberg, DJ; Gordon, F; Hutchinson, SJ; Irving, W; Lewis, H; Ryder, S; Ustainowski, A; Vilar, J; Hickman, M

COMMUNITY-BASED SCREENING FOR HEPATITIS B VIRUS INFECTION IN THE GAMBIA, WEST AFRICA: PREVALENCE OF INFECTION AND FACTORS AFFECTING THE SCREENING ATTENDANCE. (2013) Shimakawa, Y; Lemoine, M; Njai, HF; Jatta, A; Sanneh, B; Taal, M; Corrah, T; D'Alessandro, U; Njie, R; Thursz, M

Reduction of HBV replication prolongs the early immunological response to IFNα therapy. (2013) Tan, Anthony T; Hoang, Long Truong; Chin, Daniel; Rasmussen, Erik; Lopatin, Uri; Hart, Stefan; Bitter, Hans; Chu, Tom; Gruenbaum, Lore; Ravindran, Palani; Zhong, Hua; Gane, Ed; Lim, Seng Gee; Chow, Wan Cheng; Chen, Pei-Jer; Petric, Rosemary; Bertoletti, Antonio; Hibberd, Martin Lloyd

2011

Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. (2011) Martin, Natasha K; Vickerman, Peter; Foster, Graham R; Hutchinson, Sharon J; Goldberg, David J; Hickman, Matthew

PNPLA3 SEQUENCE VARIANT (RS738409) CONFERS SUSCEPTIBILITY TO LIVER DAMAGE AND CIRRHOSIS IN HCV RELATED LIVER DISEASE. (2011) Thursz, M; Corradini, SG; Toniutto, P; Molinaro, A; Palla, L; Knapp, S; Anstee, Q; Huang-Doran, I; Goldin, R; Romeo, S

2005

Update of mortality and incidence rates for intrahepatic cholangiocarcinoma and other hepatobiliary tumours in England & Wales. (2005) Khan, S; Mandeville, K; Toledano, M; Thomas, H; Taylor-Robinson, S

2004

Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. (2004) Lluch, Paloma; Torondel, Belén; Medina, Pascual; Segarra, Gloria; Del Olmo, Juan A; Serra, Miguel A; Rodrigo, José M

2002

The efficacy of tacrolimus versus microemulsified cyclosporin in prevention of early acute cellular rejection following liver transplantation: A histopathological assessment; On behalf of the UK and Republic of Ireland liver transplant study group. (2002) Arul, D; Burroughs, A; Truesdale, A; Elbourne, D; Hardy, P; Davies, S

2001

Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. (2001) Dumpis, U; Holmes, EC; Mendy, M; Hill, A; Thursz, M; Hall, A; Whittle, H; Karayiannis, P